---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-098655"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:50:20.423157+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# InMed Q1 FY2025 revenue $1.3M (+40% YoY); net loss narrows to $1.68M

## Summary
- BayMedica revenue $1.3M, up 40% YoY; BayMedica generated $0.3M net income (24% margin).
- Net loss narrowed to $1.68M ($2.17/sh) from $2.54M ($15.24/sh) in Q1 FY2024.
- Cash and equivalents $5.6M at Sep 30, 2024, down from $6.6M at June 30, 2024; expects cash to fund through Q1 calendar 2025.
- Reverse stock split effective Nov 14, 2024 to regain Nasdaq minimum bid price compliance.
- Preclinical data for Alzheimer's candidate INM-901 shows oral bioavailability and significant behavioral results; data expected Q4 2024.

## SEC filing metadata
- accession: 0001213900-24-098655
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024098655/0001213900-24-098655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024098655/ea0221397-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-098655
- JSON: https://secwatch.observer/filing/0001213900-24-098655.json
- Plain text: https://secwatch.observer/filing/0001213900-24-098655.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.